Summary of COVID-19 dimethyl fumarate studies

1. Horby et al., Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

713 patient dimethyl fumarate late treatment RCT: 3% higher mortality (p=0.89), 20% higher ventilation (p=0.65), and 12% worse 7-point scale results (p=0.41).
RCT 713 hospitalized COVID-19 patients showing no significant difference in clinical outcomes with dimethyl fumarate. 6-month results are from [Horby]
Jan 2024, Nature Communications, https://www.nature.com/articles/s41467-023-43644-x, https://c19p.org/horby14